Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

Journal of Medical Economics

Volumn 18, Issue 3, 2015, Pages 173-188

  Attard, C L ^a   Pepper, A N ^a   Brown, S T ^a   Thompson, M F ^a   Thuresson, P O ^b   Yunger, S ^c   Dent, S ^d   Paterson, A H ^e   Wells, G A ^f  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Hoffmann La Roche Ltd   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Breast cancer; Cost effectiveness analysis; Cost utility analysis; HER2 positive; Neoadjuvant; Pertuzumab; Trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PERTUZUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANADA; CANCER RECURRENCE; CLINICAL TRIAL; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; EARLY CANCER; EVENT FREE SURVIVAL; FEMALE; HEALTH CARE COST; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; ECONOMICS; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANADA; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84929297774     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.979938     Document Type: Article

References (71)

1. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68
2. Vogel UF. Confirmation of a low HER2 positivity rate of breast carcinomas-limitations of immunohistochemistry and in situ hybridization. Diagn Pathol 2010;5:50
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
4. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63-9
5. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42
6. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8
7. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9
8. Paik S, Liu ET. HER2 as a predictor of therapeutic response in breast cancer. Breast Dis 2000;11:91-102
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001;344:783-92
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
11. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
12. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236-44
13. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and adjuvant tras-tuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014;15:640-7
14. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83
15. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73
16. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 2013;382:1021-8
17. Lamond NW, Younis T. Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. Int J Womens Health 2014;6:509-21
18. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-41
19. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13
20. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;2: Cd005002
21. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81
22. Kurosumi M. Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer 2006;13:254-9
23. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85
24. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30: 1796-804
25. Kim MM, Allen P, Gonzalez-Angulo AM, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 2013;24:1999-2004
26. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9
27. de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastu-zumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014;15:1137-46
28. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164-72
29. Food and Drug Administration. Center for Drug Evaluation and Research Application Number: 125409Orig1s000, Cross Discipline Team Leader Review. Silver Spring, MD: US Department of Health & Human Services, 2013. http://www.accessdata.fda.gov/drugsat fda-docs/nda/2012/125409 Orig1s000CrossR.pdf. Accessed June 18, 2014
30. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32
31. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthra-cycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278-84
32. PCODR Expert Review Committee Final Recommendation for Pertuzumab (Perjeta Herceptin Combo Pack). Toronto, ON, Canada: Pan-Canadian Oncology Drug Review (pCODR), 2013. Last updated: August 1, 2013. http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-perjetacp-mbc-fn-rec.pdf. Accessed June 18, 2014
33. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer 2010;10:489-91
34. Swain SM, Kim SB, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013;14:461-71
35. Hoffmann-La Roche Ltd. Pertuzumab (Perjeta®) Product Monograph. Mississauga, ON, Canada: Hoffmann-La Roche Ltd., 2014. http://www.rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Perjeta/Perjeta-PM-E.pdf. Accessed July 17, 2014
36. Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist 2012;17:164-71
37. Mittmann N, Evans WK, Rocchi A, et al. Guidelines for health technologies: specific guidance for oncology products in Canada. Value Health 2012;15:580-5
38. Hoffmann-La Roche. Weighted average weight of Canadian patients treated with trastuzumab from Cancer Care Ontario (CCO) and the British Columbia Cancer Agency (BCCA). Data on File. Mississauga, ON, Canada: Hoffmann-La Roche Ltd., 2012
39. Statistics Canada. Canadian Health Measures Survey: Cycle 2 Data Table 22-Measured standing height, by age and sex, household populations, Canada, 2009 to 2011. Ottawa, ON, Canada: Government of Canada, 2013. Last updated: June 19, 2014. http://www.statcan.gc.ca/pub/82-626-x/82-626-x2013001-eng.pdf. Accessed May 9, 2014
40. Food and Drug Administration. Guidance for Industry-Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Silver Spring, MD: US Department of Health & Human Services, 2012. http://www.fda.gov/down-loads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf. Accessed June 10, 2014
41. Statistics Canada. Online Catologue 84-537-X: Table 1b-Complete life table, females, Canada, 2009-2011. Ottawa, ON, Canada: Government of Canada, 2013. http://www.statcan.gc.ca/pub/84-537-x/2013005/tbl/tbl1b-eng.htm. Accessed May 5, 2014
42. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-17
43. Wolfson MC. Health-adjusted life expectancy. Statistics Canada Health Reports 1996;8:41-6
44. Dranitsaris G, Cottrell W, Spirovski B, et al. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 2009;15:67-78
45. Attard CL, Brown S, Alloul K, et al. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol 2014;21:e41-51
46. Younis T, Rayson D, Sellon M, et al. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 2008;111:261-7
47. Ontario Drug Benefit Formulary. Ottawa, ON, Canada: Queen's Printer for Ontario, 2014. https://www.healthinfo.moh.gov.on.ca/formulary/. Accessed May 30, 2014
48. Cancer Care Ontario. Docetaxel + Pertuzumab + Trastuzumab Regimen Monograph. Toronto, ON, Canada: Government of Ontario, 2014. https://www.cancercare.on.ca/CCO-DrugFormulary/Pages/DfPdfContent.aspx? itemId282899. Accessed May 14, 2014
49. Cancer Care Ontario. FEC100/FEC100-Trastuzumab Regimen Monograph. Toronto, ON, Canada: Government of Ontario, 2013. https://www.cancercare.on.ca/CCO-DrugFormulary/Pages/DfPdf Content.aspx?itemId94861. Accessed May 14, 2014
50. Cancer Care Ontario. FEC-D/FEC-D + Trastuzumab Regimen Monograph. Toronto, ON, Canada: Government of Ontario, 2014. https://www.cancercar-e.on.ca/CCO-DrugFormulary/Pages/DfPdfContent.aspx?itemId94733. Accessed May 14, 2014
51. Cancer Care Ontario. Systemic treatment funding model, nursing and pharmacy resource intensity weights/workloads for evidence-informed regimens. Toronto, ON, Canada: Government of Ontario, 2014. Available at: https://www.cancercare.on.ca/cms/one.aspx? portalId1377&pageId300183. Accessed May 30, 2014
52. Cancer Care Ontario. Pertuzumab Drug Monograph. Toronto, ON, Canada: Government of Ontario, 2014. https://www.cancercare.on.ca/CCO-Drug Formulary/Pages/DfPdfContent.aspx?itemId278249. Accessed May 14, 2014
53. Mittmann N, Verma S, Koo M, et al. Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer. Curr Oncol 2010;17:7-16
54. Human Resources and Skills Development Canada. Work-Weekly hours worked, average hours worked per week in Ontario. 2012. http://www4.hrsdc.gc.ca/.3ndic.1t.4r@-eng.jsp?iid19. Accessed May 30, 2014
55. Government of Canada. Explore Careers-Wage Report for Pharmacist (NOC 3131-A) median salary ON. Toronto, ON, Canada: Government of Ontario, 2013. http://www.jobbank.gc.ca/LMI-report-bynoc.do?&noc3131&report Optionwage. Accessed May 30, 2014
56. Government of Ontario. Schedule of benefits for physician services under the Health Insurance Act. Toronto, ON, Canada: Government of Ontario, 2013. http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv-mn.html. Accessed January 2, 2014
57. OCCI Costing Analysis Tool. Ontario Case Costing Initiative. Toronto, ON, Canada: Government of Ontario, 2013. http://www.occp.com/mainPage. htm. Accessed May 13, 2014
58. Government of Ontario. Schedule of Benefits for Laboratory Services. Toronto, ON, Canada: Government of Ontario, 1999. http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/lab-servi-ces-sched-01-19990401.pdf. Accessed January 14, 2014
59. Madarnas Y, Joy AA, Verma S, et al. Models of care for early-stage breast cancer in Canada. Curr Oncol 2011;18(1 Suppl):S10-19
60. Grunfeld E, Dhesy-Thind S, Levine M, et al. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ 2005;172:1319-20
61. PCODR Expert Review Committee (pERC). Final Recommendation: Trastuzumab Emtansine (Kadcyla). Toronto, ON, Canada: Pan-Canadian Oncology Drug Review (pCODR), 2014. http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-kadcyla-mbc-fn-rec.pdf. Accessed July 18, 2014
62. Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1183-92
63. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40
64. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84
65. Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-4L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). ASCO Meeting Abstracts 2014;32(18 Suppl):LBA4
66. Berry D. After the Plenary: In NeoALTTO and ALTTO Trials, Neoadjvuant Response Predicts Adjuvant. The Cancer Letter (Online). Washington DC
67. The Cancer Letter Inc., 2014 (July 11, 2014). http://www.thecancerletter. com/articles/20140711-2
68. Sledge G. Counter-Point: George Sledge Responds to Berry's Letter: neoad-juvant doesn't predict adjuvant in breast cancer and Berry's rejoinder. The Cancer Letter (Online). Washington DC: The Cancer Letter Inc., 2014 (July 11, 2014). http://www.thecancerletter.com/articles/20140711-3
69. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
70. Will BP, Berthelot JM, Le Petit C, et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000;36:724-35
71. Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010;116:742-8